( NASDAQ-NMS:WCRX,NYSE:ACT )

News from actavis plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 04, 2015, 17:17 ET Actavis Announces FDA Approval of NATRELLE INSPIRA™ Round Gel-Filled Textured Breast Implants

Actavis plc (NYSE: ACT), which recently completed the acquisition of Allergan, Inc., today announced that the company has received approval from...


Jun 03, 2015, 16:05 ET Actavis to Present at the Goldman Sachs 36th Annual Global Healthcare Conference

 Actavis plc (NYSE: ACT), a leading global pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will...


Jun 02, 2015, 07:00 ET Actavis And Perrigo Receive FDA Approval Of Guaifenesin/Pseudoephedrine, The Store Brand Equivalent To Mucinex® D Tablets

Actavis plc (NYSE: ACT) and its partner Perrigo Company plc (NYSE: PRGO; TASE) announced today that Actavis has received U.S. Food and Drug...


Jun 02, 2015, 06:15 ET Actavis Affirms Commitment To Advancing Antibiotic Stewardship At White House Forum

Actavis plc (NYSE: ACT) is proud to participate in today's White House Forum on Antibiotic Stewardship, which assembles key Federal and private...


Jun 01, 2015, 07:00 ET Actavis Completes Acquisition of Auden Mckenzie

Actavis plc (NYSE: ACT) today announced that it has completed its acquisition of Auden Mckenzie Holdings Limited, a dynamic and fast growing...


May 27, 2015, 17:31 ET Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults

 Actavis plc (NYSE: ACT) announced today that VIBERZI™ (eluxadoline) was approved by the Food and Drug Administration (FDA) as a...


May 27, 2015, 09:00 ET Infectious Disease Experts, Scientists and Clinicians Join Forces on SHARE ID™ to Accelerate the Battle Against Antibiotic-resistant Infections

NEW YORK, May 27, 2015 /PRNewswire/-- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company committed to infectious disease...


May 22, 2015, 16:05 ET Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR

 Actavis plc (NYSE: ACT) today confirmed that a panel of the U.S. Court of Appeals for the Second Circuit has issued a ruling upholding a...


May 20, 2015, 16:05 ET Actavis to Present at Bernstein's Thirty-First Annual Strategic Decisions Conference 2015

 Actavis plc (NYSE: ACT), a leading global pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will...


May 18, 2015, 08:00 ET Actavis Launches NAMZARIC™ (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease

 Actavis plc (NYSE: ACT) today announced that NAMZARIC™ (memantine hydrochloride extended-release and donepezil hydrochloride), a...


May 12, 2015, 16:05 ET Actavis to Present at UBS Global Healthcare Conference 2015

 Actavis plc (NYSE: ACT), a leading global pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will...


May 11, 2015, 06:30 ET Actavis Reports Exceptional Performance in First Quarter 2015 with 59% Increase in Net Revenue to $4.2 Billion and 23% Growth in Non-GAAP EPS to $4.30

Actavis plc (NYSE: ACT) today reported continued exceptional performance with net revenue increasing 59 percent to $4.23 billion for the quarter...


May 07, 2015, 16:05 ET Actavis to Re-launch Generic Pulmicort RESPULES® Following Favorable Appeals Court Ruling

 Actavis plc (NYSE: ACT) today announced that it will immediately re-launch its generic version of AstraZeneca's Pulmicort RESPULES®...


Apr 28, 2015, 16:15 ET Actavis and Medicines360 Announce Publication of ACCESS IUS Efficacy and Safety Study of LILETTA™ (Levonorgestrel-Releasing Intrauterine System) 52 mg in Contraception

 Actavis plc (NYSE: ACT), a leading global pharmaceutical company and leader in women's health care, and Medicines360, a nonprofit women's...


Apr 24, 2015, 09:25 ET Actavis Announces Topline Phase 3 Clinical Trial Results for Single-Dose DALVANCE® (dalbavancin) in the Treatment of ABSSSI

 Actavis plc (NYSE: ACT) today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of...


Apr 23, 2015, 08:00 ET Actavis Launches AVYCAZ™ (Ceftazidime-Avibactam) Anti-Infective In U.S.

 Actavis plc (NYSE: ACT) today announced AVYCAZ™ (ceftazidime-avibactam) is now available for ordering by hospitals across the United...


Apr 20, 2015, 16:15 ET Actavis Announces Retirement of Charles M. Mayr

Actavis plc (NYSE: ACT) today announced that Charles M. Mayr, Chief Communications Officer, will retire from Actavis on May 15, 2015 due...


Apr 20, 2015, 08:00 ET Actavis Announces FDA Approval of Expanded Label for BOTOX® (OnabotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Adults

 Actavis plc (NYSE: ACT), which recently completed the acquisition of Allergan, today announced that the United States Food and Drug...


Apr 16, 2015, 09:00 ET Actavis to Host First Quarter 2015 Earnings Conference Call and Webcast

 Actavis plc (NYSE: ACT) today announced that it intends to release first quarter 2015 financial results on Monday, May 11, 2015, prior to the...


Apr 13, 2015, 09:22 ET Actavis and Medicines360 Announce U.S. Availability of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years

 Actavis plc (NYSE: ACT), a leading global pharmaceutical company and leader in women's health care, and Medicines360, a nonprofit women's...


Apr 08, 2015, 08:00 ET Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis

 Rhythm, a biopharmaceutical company, and Actavis plc (NYSE: ACT), a leading global pharmaceutical company, announced today the initiation of a...


Apr 08, 2015, 07:30 ET Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis

Rhythm, a biopharmaceutical company, and Actavis plc (NYSE: ACT), a leading global pharmaceutical company, announced today the initiation of a Phase...


Apr 03, 2015, 08:00 ET Actavis Confirms Generic Letairis® Patent Challenge

 Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug...


Mar 17, 2015, 09:10 ET Actavis Announces Michael R. Gallagher and Peter J. McDonnell to Join Board of Directors

 Actavis plc (NYSE: ACT) today announced that two former members of the Allergan Board of Directors - Michael R. Gallagher, Lead Independent...


Mar 17, 2015, 08:55 ET Actavis Completes Allergan Acquisition

 Actavis plc (NYSE: ACT) today announced that it has completed the acquisition of Allergan, Inc. (NYSE: AGN) in a cash and equity transaction...